Multicentre 2x2 Factorial Randomised Study Comparing Tirofiban Versus Abciximab and SES Versus BMS in AMI
Launched by MARCO VALGIMIGLI · Sep 27, 2005
Trial Information
Current as of June 09, 2025
Unknown status
Keywords
ClinConnect Summary
The combination abciximab plus bare metal stent (BMS) is currently considered the standard therapy for AMI. The use of sirolimus eluting stent (SES) is related to a reduction of the need for urgent target vessel revascularization (TVR). With current acquisition prices for abciximab and SES, replacing abciximab with tirofiban, administered as a single high-dose bolus (SHDB) regimen, is a promising strategy that would preserve financial resources. In a recent study the combination tirofiban and SES resulted to be associated to an overall lower major adverse cardiovascular events (MACE) rate w...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • ST segment elevation myocardial infarction
- • Schedule for primary percutaneous coronary intervention
- • Informed consent
- Exclusion Criteria:
- • Administration of fibrinolytic or any GP IIb/IIIa inhibitors for the treatment of current acute myocardial infarction or within 1 month before it
- • History of bleeding diathesis or allergy to the studies drug
- • Major surgery within 30 days
- • Limited life expectancy, e.g. neoplasms, others
- • Pregnancy
About Marco Valgimigli
Marco Valgimigli is a distinguished clinical trial sponsor renowned for his expertise in cardiovascular medicine and clinical research. With a focus on advancing innovative therapeutic strategies, Valgimigli leads comprehensive clinical trials aimed at improving patient outcomes in cardiovascular interventions. His commitment to evidence-based practices and collaboration with multidisciplinary teams fosters the development of cutting-edge solutions that address pressing healthcare challenges. Through a rigorous approach to trial design and execution, Valgimigli contributes significantly to the field, driving forward the understanding and treatment of cardiovascular diseases.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Ferrara, , Italy
Patients applied
Trial Officials
Roberto Ferrari, Professor
Study Chair
Cattedra di Cardiologia, Azienda Ospedaliera Universitaria di Ferrara, Italy
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials